| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MLN2480 | CTRPv2 | pan-cancer | AAC | 0.26 | 5e-06 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.17 | 3e-05 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | 0.22 | 3e-05 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-05 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.16 | 7e-05 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0001 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.17 | 0.0002 |
| mRNA | BRD-K71781559 | CTRPv2 | pan-cancer | AAC | 0.16 | 0.0002 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | -0.15 | 0.0002 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.15 | 0.0002 |